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In almost all countries in Europe alcohol is one of the top five 
potentially modifiable risk factors causing disease and disability 
(http://www.healthmetricsandevaluation.org/gbd/country-pro-
files), and in the eastern part of Europe the number one risk factor 
(Lim et al., 2012).  In the UK alcohol is now the leading cause of 
death in men between the ages of 16–54 years, accounting for 
over 20% of the total (http://www.nwph.net/nwpho/publications/
alcoholattributablefractions.pdf).  Europeans above 15 years of 
age in the EU on average drink 9800 g of pure alcohol per year – 
twice that of the rest of the world (Shield et al., 2012; for compari-
son see World Health Organization (WHO), 2011). Alcohol 
should therefore be a public health priority, but it is not (Anderson 
and Baumberg, 2006, http://www.ec.europa.eu/health/ph_deter-
minants/life_style/alcohol/documents/alcohol_europe.pdf).  This 
paper puts forward a new approach to reduce alcohol use and 
attributable harms with the potential to have major public health 
and social impacts. Our approach is simple, so it would be easy to 
introduce, and because it lacks stigmatising issues such as the 
diagnosis of addiction and dependence (Schomerus et al., 2011), it 
should be uncontentious.
The scale of the problem
The health damage caused by alcohol in European regions is 
shown in Figure 1 – it is large and spread across many organs 
systems, in addition to societal impacts. The beneficial impacts of 
alcohol on ischaemic disease and diabetes are minimal compared 
to the burden (see Figure 1), but relatively most pronounced in 
Western Europe. Just to give some examples of specific health 
harms: more than three-quarters of liver cirrhosis deaths, 7% of 
cancer deaths and 25% or injury deaths in adults under 65 years of 
age in Europe in 2004 were estimated to be due to alcohol (Rehm 
et al., 2012). In total, the annual social costs to EU countries of 
alcohol damage have been estimated at €125 billion in 2003, 
which corresponds to 1.3% of the gross domestic product of these 
countries (Anderson and Baumberg, 2006).
In most areas of harm, and certainly in terms of health, the 
negative impacts of alcohol increase in a non-linear way with 
intake (Rehm et al., 2010, 2011). As intake increases, there is an 
exponential increase in harms – see Figure 2(a) for the example of 
injuries (see Rehm et al., 2011, for a similar risk curve for chronic 
disease). This means that for intakes of more than 50 g pure alco-
hol per day (two-thirds of a bottle of wine or equivalent), any 
decrease in alcohol consumption gains proportionately more in 
terms of health gains. As shown in Figure 2(b) for injury fatalities, 
halving intake from 100 to 50 g per day gives an eight-fold benefit 
in terms of reducing health harms (see also Rehm and Roerecke, 
2013, for examples of the effect of reducing drinking on all-cause 
mortality). Note that this example is specific for alcohol use, and 
only applies as the mortality risk curve for this substance and mor-
tality outcomes are exponential. The risks of other substances on 
mortality may have different shapes.
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Figure 1. Percentage of disability-adjusted life years (DALYs) due to risk factors in three different regions of Europe: (a) percentage of Western 
Europe DALYs, 2010; (b) percentage of Central Europe DALYs, 2010; (c) percentage of Eastern Europe DALYs, 2010. Source data obtained 
from Global Burden of Disease and Injury 2010 Study from Institute of Health Metrics and Evaluation, Seattle, Washington (http://www.
healthmetricsandevaluation.org/gbd/country-profiles).
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It therefore follows that any interventions that reduce the 
amount of alcohol drunk will reduce harms so we should be devel-
oping policies that reduce alcohol intake. Less alcohol means bet-
ter health in the same way that a lower blood pressure and lower 
cholesterol means less risk of heart attacks and stroke. Proven 
policies to reduce alcohol consumption exist (Anderson et al., 
2009) and can readily be developed into both personal and public 
health agendas as discussed below.
A ten point plan
The personal approach – four steps to better 
health
1. Know your number.
 People need to know their alcohol intake in terms of 
grams per average day the way they (should) know their 
calorie intake, their cholesterol level and their blood 
pressure. Gram measures are a global standard and so are 
to be preferred to units which vary from country to 
country.
2. Target your intake less than 20 g/day for men and 15 g/
day for women.
 These levels of intake are not ‘safe’ but represent a threshold 
of harms that most authorities consider an acceptable level in 
relation to the pleasures of alcohol. Above these levels, the 
harms of alcohol begin to accelerate as intake increases.
3. Take pride in lowering your number.
 Just as a lower number for blood pressure and cholesterol 
give greater life expectancy, so lower alcohol intake leads 
to improved longevity and health. With all these major 
sources of ill health 'less is more'.
4. Take two drink-free days per week.
 The past 50 years have seen a major change in the use of 
alcohol in the UK. Whereas in the 1950s alcohol was seen 
as a luxury it is now widely perceived as a dietary staple 
and many people drink with every evening meal. There is 
evidence that short periods of not drinking, even for a 
day, can help the liver recover from the effects of alcohol 
and so reduce the risk of liver complications such as fatty 
liver and cirrhosis (Marugame et al., 2007; http://www.
publications.parliament.uk/pa/cm201012/cmselect/
cmsctech/1536/153602.htm). 
The policy approach - six points for 
governments
There are many proven interventions that will reduce alcohol con-
sumption and thus harms. The top six interventions, in no particu-
lar order, are:
Instigate minimum pricing of alcohol at the 
level of 5 pence (0.06 Euro) per gram
This would reduce the consumption of cheap alcohol without 
affecting that of quality products and has two main actions: it helps 
deter young people initiating drinking as these are the most cost-
sensitive group; it also reduces consumption in very heavy drink-
ers (Purshouse et al., 2010) which, as can be seen from Figure 2, 
produces disproportionately major health gains. Overall, minimum 
pricing is a focused instrument within the general family of pricing 
policies which have shown to be very effective measures to reduce 
drinking and related harm (Wagenaar et al., 2009).
Require the labelling of grams per bottle of drink
This would make it much easier for people know exactly how much 
they are consuming. This would be quite straightforward for the pro-
ducer as the concentration of alcohol is currently displayed so the 
amount in grams is known. All that is required is changing the label.
Limit the places and times at which ‘strong’ 
alcohol can be bought
This would apply to purchase outside of a licensed premise such 
as a supermarket. Sweden does this to good effect (for a 
Figure 2. Lifetime risk of death due to alcohol-related injury, and the 
effect of reduction of consumption (adapted from Rehm J, Zatonski 
W, Taylor B, et al. (2011) Epidemiology and alcohol policy in Europe. 
Addiction 106: S11–S19 with permission from John Wiley & Sons, Inc).
(a) shows the exponential rise in alcohol-related injury deaths with 
increase in intake; (b) shows how a 50% reduction in consumption from 
100 g/day gives an eight-fold benefit in terms of harm. Note that these 
calculations are based on sustained changes.
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comparison of alcohol-attributable harm in Sweden to the rest of 
EU see Rehm et al., 2012; Shield et al., 2013). The Swedes have 
to plan their purchase of strong alcohol (defined as alcohol more 
than 35 g/L pure alcohol) between the hours of 0900–1700 on 
weekdays and 0900–1300 on weekends. This makes impulse 
buying, particularly when drunk, almost impossible. It makes 
people think about alcohol as a luxury and not a necessity, and 
makes it easier for people with drinking-control problems to avoid 
contact with alcohol in shops and supermarkets.
Encourage the use of proven treatments for 
alcohol dependence
Several effective treatments exist, yet despite this fewer than one in 
10 people with alcohol dependence in Europe are offered treat-
ments (Alonso et al., 2004; Rehm et al., 2013a; Rehm et al., 2013c). 
Treatments include proven effective psychosocial treatments 
(Martin and Rehm, 2012) as well as pharmacological treatments: 
acamprosate, naltrexone and nalmefene, all of which have good 
evidence from modern trials of efficacy (Rösner et al., 2010a, 
2010b). These can provide very significant health benefits to indi-
viduals and society and should be offered to all people with an 
alcohol dependence problem (see Rehm et al., 2013c, for potential 
public health gains; see Laramée et al. 2013, for potential eco-
nomic savings). Other drug treatments with some evidence are 
sodium oxybate which has been licensed in Italy and Austria for 
many years, and baclofen (reviewed in Chick and Nutt, 2012). 
Disulfiram is an older treatment that works in some people but is 
underused and little researched (see guidelines of National 
Association for Health and Clinical Excellence (NICE), 2011). A 
better understanding of its mode of action might lead to improved 
versions and improved targeting of treatment. Anti-glutamate 
drugs such as topiramate also have shown efficacy (Johnson et al., 
2007). The widening of treatments should be synchronised with 
acceptance of treatment goals other than abstinence, which may 
also help closing the treatment gap (Marlatt, 2001; Van Amsterdam 
and van den Brink, 2013).
Incentivise investment in research to help 
those with alcohol dependence
The brain mechanisms of alcohol's actions and dependence are 
becoming better understood but there is still much to do. Despite 
promising targets for interventions such as the GABAB and dopa-
mine receptors very little research is being done.  In the UK, gov-
ernment sponsored research spend on addiction is tiny in 
comparison with the scale of the problem, even though addiction 
is a priority of the UK Medical Research Council. 
Similar problems are seen in relation to the toxic effects of alco-
hol: although most of the patients in liver clinics have alcohol-related 
liver disease (Rehm et al., 2013b), less than 10% of the research 
carried out on liver disease is on alcohol-related harms. No drugs to 
treat alcohol-induced liver disease are available which in effect 
means that liver transplantation is the sole intervention for end-stage 
alcohol liver disease – a hugely expensive and limited option.
There is a pressing need to develop new approaches and use 
modern patient stratification techniques such as genetics and 
neuro-imaging measures to optimise current ones. Pharmaceutical 
investment in alcohol treatments is minimal and should be revital-
ised by government incentives.
Support the development of alcohol 
alternatives with safer profiles and antidotes
The story of snus is the model here: snus, a buccally-active tobacco 
preparation, is much less harmful than smoked tobacco (Luo et al., 
2007). Sweden has for many decades made this available in a spe-
cific and hugely successful attempt to reduce the proportion of 
Swedes smoking. It is responsible for them having one of the low-
est rates of lung cancer in Western Europe (http://globocan.iarc.fr/
factsheets/cancers/lung.asp).  Modern science could make drugs 
that have similar beneficial properties to alcohol (relaxation, hap-
piness, sociability) but without or with less of the unwanted effects 
(unsteadiness, anger, addiction, death in overdose) (Nutt, 2006). 
These drugs would also have the benefit of having antidotes that 
people could use to sober up and so, for example, drive themselves 
home after a party. If such drugs took over just part of the alcohol 
market they would pay for themselves many times over by reduc-
ing the vast costs of alcohol damage. The only reason that they are 
not yet currently marketed is that the producing companies do not 
have the assurance that governments would allow them to be sold. 
This needs to be made explicit so that research can go ahead with 
knowledge that success would be rewarded.
Conclusion
We have presented a clear, simple and evidence-based approach 
to reducing the public and personal harms and costs of alcohol-
attributable health damage that focuses on numbers not disease 
of diagnosis. It involves education and self-monitoring 
approaches that have already been established to work in rela-
tion to calories, cholesterol and blood pressure. Our approach is 
likely to be effective if properly rolled out and would have 
major beneficial effects on other effects of alcohol such as 
crime, road accidents and personal violence as well as public 
health.
One major advantage of the numeric approach is that it does 
not limit interventions by requiring medical professionals to 
make a diagnosis of an illness such as alcohol dependence and 
addiction in anyone. This is a major advance on what happens 
today as treatment is usually limited to those with a diagnosis. 
The focus on grams rather than illness would lead to considera-
ble savings in medical time and would avoid diagnostic mistakes 
that could lead to a professional not recommending an interven-
tion. It corresponds to the focus on blood pressure reading rather 
than on labelling associated disease processes (and the disease 
processes could, similarly to hypertension, be relabelled 'heavy 
drinking', so interventions would be covered – Rehm et al., 
2013c). This focus thus avoids the stigma of labelling someone 
as alcohol-dependent or addicted. Major gains in health have 
come from treating and preventing tobacco use without the need 
to label smokers as being ill. We believe that alcohol interven-
tions would be more widely effective if that same attitude was 
taken in relation to drinkers.
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